#DYK? Biologics have shown to be effective in treating patients with severe asthma. Learn more: bit.ly/3RNvs5r

There are several barriers that make it difficult for older patients to access biological medications, including: ✋ Hesitancy 🧪 Access to infusion centers 🚗 Transportation 📚 Education 📃 Insurance coverage Learn more: bit.ly/46mBxM2

Developing breakthrough biologics isn’t an inexpensive investment. Biosimilars, however, have become a well-respected but less costly alternative to their reference products. Read more: healthpolicytoday.org/2022/11/03/vol…

Biological medications offer innovative treatment options for patients with a neurological disorder. The FDA has already approved biologics to treat a range of neurological disorders, and several biosimilars are in the pipeline for approval. Learn more: bit.ly/3OTezUN

Biosimilars were introduced to expand treatment options, lower health care costs, and reduce patient spending. Progress has been made, but there is still work to do for biosimilars to reach their full potential. Learn more: bit.ly/3VrLjIn

#DYK There are six FDA-approved biologics for treating asthma, and they are proven to be effective. Learn more: bit.ly/3RNvs5r

“We need to be thinking of the future. The policy that is established now is going to drive investment and drive biosimilars into the future.” Amgen’s Chad Pettit highlights the critical role policymaking plays in the development of biologics. #AfPASummit25

"Biosimilars allow patients to get treated earlier in their disease state, allowing them to achieve better outcomes." American College of Rheumatology Colby Tiner discusses how biosimilars have been a boon for rheumatology patients.

“It should be effective, safe, and make the most responsible use of limited resources.” safebiologics.org Phil Schneider talks about the FDA’s responsibility to look at safety and efficacy and not cost.

“The research has been clear, biosimilars have been just as effective as originators. It’s a matter of making this a priority.” American College of Rheumatology's Colby Tiner discusses the benefits of biosimilars and the need to educate legislators and regulators on this issue.

#DYK? There are three types of biologic medications: 🧪 Innovator biologics 🧪Biosimilars 🧪Interchangeable biosimilars Learn more: bit.ly/3Xr0HGD

There are more than 40 million older patients in America, and policymakers have a responsibility to ensure these patients have access to the right care. Learn more: bit.ly/46mBxM2

Prescription drugs are not simply a cost item in the US health care budget; they are a critical investment that underpins the nation’s health, economic vitality and overall societal well-being. Learn more: bit.ly/4729P9l

Do you know the differences between #biosimilars and #generics? Learn them here: bit.ly/3CxcZFo

#Biosimilars have provided some increased patient access and options to care, but access has been influenced by distribution and reimbursement. Learn more: bit.ly/4flPGMr

DYK? While "Most Favored Nation" policies will target brand products without generic or biosimilar competition, the overall downward pressure on prices could affect the market for future biosimilars. Learn more: bit.ly/4gI7inW

Biosimilars have opened new doors for patient care, but some barriers remain. Several factors affect patients’ ability to access biosimilars: 🏥 Site of care 🪪 Type of insurance 💸 Pricing Incentives Learn more: bit.ly/4oSgMQx

Prescription drugs are not simply a cost item in the US health care budget; they are a critical, strategic investment that underpins the nation’s health, economic vitality, and overall societal well-being. Learn more: bit.ly/4729P9l

Older patients deserve high-quality care, and biological medications provide valuable treatment options. Learn more: bit.ly/46mBxM2

For some patients, a self-administered biologic is the right option. But access to these treatments can be riddled with roadblocks. Learn more: bit.ly/4aRaMAa